Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma

INTRODUCTION: Dupilumab, a fully human anti-IL-4Rα monoclonal antibody, inhibits signaling of both interleukin (IL)-4 and IL-13, which are key drivers of type 2-mediated inflammation. Dupilumab is approved in the EU, USA, and other countries for the treatment of adults with inadequately controlled m...

詳細記述

保存先:
書誌詳細
出版年:Adv Ther
主要な著者: Busse, William W., Maspero, Jorge F., Rabe, Klaus F., Papi, Alberto, Wenzel, Sally E., Ford, Linda B., Pavord, Ian D., Zhang, Bingzhi, Staudinger, Heribert, Pirozzi, Gianluca, Amin, Nikhil, Akinlade, Bolanle, Eckert, Laurent, Chao, Jingdong, Graham, Neil M. H., Teper, Ariel
フォーマット: Artigo
言語:Inglês
出版事項: Springer Healthcare 2018
主題:
Study Protocol
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5960488/
https://ncbi.nlm.nih.gov/pubmed/29725983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-018-0702-4
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料